Pharmacodynamic Effects of Riociguat in Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction
Status:
Completed
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to
• Assess the pharmacodynamic profile of riociguat in subjects with symptomatic pulmonary
hypertension and heart failure with preserved ejection fraction
The secondary objectives of this study are to
- Assess safety and tolerability of riociguat in this study population
- Assess changes in dimensions of left and right ventricles and cardiac function
parameters using cardiac magnetic resonance imaging